Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Plans $100 Million C Round; Then Hong Kong IPO

publication date: Jan 19, 2018

Ascletis, a Hangzhou company developing a oral interferon-free combination treatment for hepatitis C, is planning a $100 million C funding. The company will use the money to fund clinical trials and develop a marketing operation. Previously, Ascletis raised $155 million in two rounds of venture capital, plus another $100 million in startup investment. After the C Round, Ascletis is considering an IPO in Hong Kong, the exchange of choice for young China biopharmas now that it no longer requires several years of profitable operations before listing. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital